These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 19412734)

  • 1. The substrate domain of BCAR1 is essential for anti-estrogen-resistant proliferation of human breast cancer cells.
    Brinkman A; de Jong D; Tuinman S; Azaouagh N; van Agthoven T; Dorssers LC
    Breast Cancer Res Treat; 2010 Apr; 120(2):401-8. PubMed ID: 19412734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer oestrogen independence mediated by BCAR1 or BCAR3 genes is transmitted through mechanisms distinct from the oestrogen receptor signalling pathway or the epidermal growth factor receptor signalling pathway.
    Dorssers LC; van Agthoven T; Brinkman A; Veldscholte J; Smid M; Dechering KJ
    Breast Cancer Res; 2005; 7(1):R82-92. PubMed ID: 15642172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response.
    van Agthoven T; Sieuwerts AM; Meijer D; Meijer-van Gelder ME; van Agthoven TL; Sarwari R; Sleijfer S; Foekens JA; Dorssers LC
    Endocr Relat Cancer; 2010 Mar; 17(1):215-30. PubMed ID: 19966015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tamoxifen treatment promotes phosphorylation of the adhesion molecules, p130Cas/BCAR1, FAK and Src, via an adhesion-dependent pathway.
    Cowell LN; Graham JD; Bouton AH; Clarke CL; O'Neill GM
    Oncogene; 2006 Dec; 25(58):7597-607. PubMed ID: 16799644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCAR1, a human homologue of the adapter protein p130Cas, and antiestrogen resistance in breast cancer cells.
    Brinkman A; van der Flier S; Kok EM; Dorssers LC
    J Natl Cancer Inst; 2000 Jan; 92(2):112-20. PubMed ID: 10639512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer.
    Meijer D; Jansen MP; Look MP; Ruigrok-Ritstier K; van Staveren IL; Sieuwerts AM; van Agthoven T; Foekens JA; Dorssers LC; Berns EM
    Breast Cancer Res Treat; 2009 Jan; 113(2):253-60. PubMed ID: 18299979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance.
    van Agthoven T; Sieuwerts AM; Meijer-van Gelder ME; Look MP; Smid M; Veldscholte J; Sleijfer S; Foekens JA; Dorssers LC
    J Clin Oncol; 2009 Feb; 27(4):542-9. PubMed ID: 19075277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells.
    Manuvakhova M; Thottassery JV; Hays S; Qu Z; Rentz SS; Westbrook L; Kern FG
    Oncogene; 2006 Sep; 25(44):6003-14. PubMed ID: 16682955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression changes during the development of estrogen-independent and antiestrogen-resistant growth in breast cancer cell culture models.
    Pennanen PT; Sarvilinna NS; Ylikomi TJ
    Anticancer Drugs; 2009 Jan; 20(1):51-8. PubMed ID: 19343000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic value of BCAR1 in patients with primary breast cancer.
    Dorssers LC; Grebenchtchikov N; Brinkman A; Look MP; van Broekhoven SP; de Jong D; Peters HA; Portengen H; Meijer-van Gelder ME; Klijn JG; van Tienoven DT; Geurts-Moespot A; Span PN; Foekens JA; Sweep FC
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6194-202. PubMed ID: 15448007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment.
    van der Flier S; Brinkman A; Look MP; Kok EM; Meijer-van Gelder ME; Klijn JG; Dorssers LC; Foekens JA
    J Natl Cancer Inst; 2000 Jan; 92(2):120-7. PubMed ID: 10639513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
    Hoffmann J; Sommer A
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth.
    Britton DJ; Hutcheson IR; Knowlden JM; Barrow D; Giles M; McClelland RA; Gee JM; Nicholson RI
    Breast Cancer Res Treat; 2006 Mar; 96(2):131-46. PubMed ID: 16261397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural insights into the association between BCAR3 and Cas family members, an atypical complex implicated in anti-oestrogen resistance.
    Garron ML; Arsenieva D; Zhong J; Bloom AB; Lerner A; O'Neill GM; Arold ST
    J Mol Biol; 2009 Feb; 386(1):190-203. PubMed ID: 19103205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells.
    Aesoy R; Sanchez BC; Norum JH; Lewensohn R; Viktorsson K; Linderholm B
    Mol Cancer Res; 2008 Oct; 6(10):1630-8. PubMed ID: 18922978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A metastatic breast tumor cell line, GI-101A, is estrogen receptor positive and responsive to estrogen but resistant to tamoxifen.
    Morrissey JJ; Raney S
    Cell Biol Int; 1998; 22(6):413-9. PubMed ID: 10328849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional identification of genes causing estrogen independence of human breast cancer cells.
    van Agthoven T; Veldscholte J; Smid M; van Agthoven TL; Vreede L; Broertjes M; de Vries I; de Jong D; Sarwari R; Dorssers LC
    Breast Cancer Res Treat; 2009 Mar; 114(1):23-30. PubMed ID: 18351453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.
    Holm C; Rayala S; Jirström K; Stål O; Kumar R; Landberg G
    J Natl Cancer Inst; 2006 May; 98(10):671-80. PubMed ID: 16705121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients.
    Speirs V; Malone C; Walton DS; Kerin MJ; Atkin SL
    Cancer Res; 1999 Nov; 59(21):5421-4. PubMed ID: 10554009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.